Literature DB >> 17089039

LY-6K gene: a novel molecular marker for human breast cancer.

Ji Woo Lee1, Yeon Su Lee, Kyung Hyun Yoo, Kee Ho Lee, Kyunghee Park, Taejin Ahn, Christopher Ko, Jong Hoon Park.   

Abstract

A full-length cDNA was identified using one STS sequence containing an SNP (single nucleotide polymorphism) derived from genomic DNAs of breast cancer patients using a variety of bioinformatics tools. The cDNA encodes LY-6K, a novel member protein of the Ly-6/uPAR superfamily. It has been annotated as a target antigen for the HNSCC (head-and neck squamous cell carcinoma). We isolated the LY-6K gene from genomic DNAs obtained from breast cancer patients through large scale, case-control-screening. We performed northern blot hybridization and semi-quantitative RT-PCR on a human multiple-tissue mRNA blot from several breast cancer patients. We investigated the expression level of the LY-6K gene in human breast cancer, and compared this to expression in human normal breast tissue. We found that LY-6K was more highly expressed in the mRNA of breast tumors compared to its expression in normal breast tissue. These results suggest that LY-6K is not only a target antigen for HNSCC but also a significant new molecular marker for diagnosis and gene therapy in patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17089039

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

1.  Stem cell antigen-1 deficiency enhances the chemopreventive effect of peroxisome proliferator-activated receptorγ activation.

Authors:  Hongyan Yuan; Geeta Upadhyay; Yuzhi Yin; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-28

2.  The regulatory mechanism of the LY6K gene expression in human breast cancer cells.

Authors:  Hyun Kyung Kong; Sukjoon Yoon; Jong Hoon Park
Journal:  J Biol Chem       Date:  2012-09-17       Impact factor: 5.157

Review 3.  Regulation of cell signalling by uPAR.

Authors:  Harvey W Smith; Chris J Marshall
Journal:  Nat Rev Mol Cell Biol       Date:  2010-01       Impact factor: 94.444

4.  Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer.

Authors:  Hajime Ishikawa; Motohiro Imano; Osamu Shiraishi; Atsushi Yasuda; Ying-Feng Peng; Masayuki Shinkai; Takushi Yasuda; Haruhiko Imamoto; Hitoshi Shiozaki
Journal:  Gastric Cancer       Date:  2013-04-24       Impact factor: 7.370

5.  Using LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling.

Authors:  Julie M Kneller; Thomas Ehlen; Jasenka P Matisic; Dianne Miller; Dirk Van Niekerk; Wan L Lam; Marco Marra; Rebecca Richards-Kortum; Michelle Follen; Calum Macaulay; Steven J M Jones
Journal:  Biomark Insights       Date:  2007-12-11

6.  LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling.

Authors:  R Matsuda; H Enokida; T Chiyomaru; N Kikkawa; T Sugimoto; K Kawakami; S Tatarano; H Yoshino; K Toki; Y Uchida; K Kawahara; K Nishiyama; N Seki; M Nakagawa
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

7.  Systematic analysis of secreted proteins reveals synergism between IL6 and other proteins in soft agar growth of MCF10A cells.

Authors:  Sofie C Van Huffel; Jill M Tham; Xiaoqian Zhang; Kohpang Lim; Chunxuan Yang; Yikloo Tan; Felicia Ong; Ian Lee; Wanjin Hong
Journal:  Cell Biosci       Date:  2011-03-25       Impact factor: 7.133

8.  miRNAs involved in LY6K and estrogen receptor α contribute to tamoxifen-susceptibility in breast cancer.

Authors:  Ye Sol Kim; Sae Jeong Park; Yeon Seon Lee; Hyun Kyung Kong; Jong Hoon Park
Journal:  Oncotarget       Date:  2016-07-05

Review 9.  Characterization and function of human Ly-6/uPAR molecules.

Authors:  Hyun Kyung Kong; Jong Hoon Park
Journal:  BMB Rep       Date:  2012-11       Impact factor: 4.778

10.  Epigenetic activation of LY6K predicts the presence of metastasis and poor prognosis in breast carcinoma.

Authors:  Hyun Kyung Kong; Sae Jeong Park; Ye Sol Kim; Kyoung Min Kim; Hyun-Woo Lee; Hyeok-Gu Kang; Yu Mi Woo; Eun Young Park; Je Yeong Ko; Hiromu Suzuki; Kyung-Hee Chun; Erwei Song; Kyu Yun Jang; Jong Hoon Park
Journal:  Oncotarget       Date:  2016-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.